Agilent Technologies, Inc.
Life Sciences & Chemical Analysis
P.O. Box 51000
Santa Clara, CA, 92055-1000
Website: http://www.agilent.com/chem
|
 |
Microarray And Software For Comparative Genomic Hybridization Studies In Cancer Research
Human Genome CGH Microarray and CGH Analytics software (Agilent Technologies, Inc.) aids cancer biologists and cytogeneticists in the study of genomic alterations in cancer. Comparative genomic hybridization (CGH) is used to study the chromosomal changes that frequently occur in cancer cells, including the loss or duplication of regions of chromosomal DNA. This microarray-based CGH product enables rapid exploration of chromosomal changes on the same platform used to study gene expression changes. The Agilent Human Genome CGH Microarray provides genome-wide coverage with an emphasis on the most commonly studied genomic coding regions and cancer-related genes. It includes 40,000 probes that span the human genome with an average spatial resolution of approximately 75 kb, including coding and non-coding sequences. Using 60-mer oligonucleotide probes provides high sensitivity, enabling reliable identification of both highly localized and broadly extended single copy deletions, homozygous gene deletions and amplicons. The gene-focused content of the Agilent CGH array facilitates comparison of CGH and gene expression data so that researchers can correlate genomic copy number changes with gene expression changes. Only 25 nanograms of total genomic DNA is needed to detect chromosomal changes across the entire genome. The use of total genomic DNA improves experimental design and ease of use.
CGH Analytics software provides a visual environment for exploring array-CGH data. Based on technology developed in Agilent Labs, it uses information visualization theory to leverage visual perception as a means to find interesting patterns in data. The software provides simultaneous visualization of multiple CGH microarray profiles; user-selectable calibration for comparison of profiles; statistical measures to detect aberrant regions; simultaneous chromosome plotting at multiple zoom levels; preloaded gene annotation information from the most recent genome builds; and more.
|
|
